Biopharma firm IN8bio's Q2 net loss narrows as expenses decline

IN8bio

06/08/2026 21:16

Overview
US biopharma firm's Q2 net loss narrowed yr/yr, with flat R&D and lower G&A expenses
Company reported updated clinical data showing improved survival for glioblastoma patients on DeltEx DRI
Cash position rose to $18 mln at June 30, 2026, from $13.2 mln a year earlier

Outlook
Company expects to report initial preclinical animal data for INB-619 in H2 2026
Company anticipates providing updates on FDA discussions for DeltEx DRI GBM program
IN8bio plans to provide a clinical update on INB-100 program in late 2026

Result Drivers
CLINICAL DATA - Co reported updated clinical and peer-reviewed data showing improved survival and progression-free survival for glioblastoma patients treated with DeltEx DRI
SAFETY PROFILE - Co said DeltEx DRI showed favorable safety with no dose-limiting toxicities, CRS or ICANS in newly diagnosed GBM patients
IMMUNE REMODELING - Co reported translational analyses showing DeltEx DRI preserved immune function and remodeled the tumor microenvironment in GBM

Company press release: ID:nGNX327ZJH

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Loss
 
$4.78 mln
 
Q2 Loss Per Basic Share
 
$0.25
 
Q2 Operating Expenses
 
$4.94 mln
 
Q2 Operating Income
 
-$4.78 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for IN8bio, Inc. is $5.50, about 456.2% above its August 5 closing price of $0.99

Reuters Recommended Reads
Aug 6 - CG Oncology Q2 net loss widens on higher R&D costs
Aug 6 - ALX Oncology Q2 net loss narrows on lower R&D costs
Aug 4 - Rhythm's drug shows promise for brain tumor-related weight condition in small study 

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)